OPEX Ratio Alignment & Portfolio Valuation Overview
CLINICS & DIAGNOSTICS BUSINESS
OPERATING PERFORMANCE OVERVIEW
REVENUE DEVELOPMENT²
+88.6%
+3.2%
EBITDA¹ DEVELOPMENT
GEORGIA
CAPITAL
+101.3%
+84.2%
45
47
-31.7%
10
12
-62.1%
13
7
25
24
60
35
19
32
3
11
8
21
3
2
1
17
2
15
9
2Q20
2Q21
2Q22
1H20
1H21
1H22
2Q20
2Q21
2Q22
1H20
1H21
1H22
■Clinics
Diagnostics
- Total
■Clinics
Diagnostics
CLINICS & DIAGNOSTICS
KEY DRIVERS
■ Similar to the hospitals business, our clinics
business was also impacted by the
suspension of COVID contracts by the
Government.
◉
Substantially lower COVID cases during
the quarter resulted in a significant
decrease in diagnostics business revenues
and EBITDA.
The growth is expected to rebound over the
next few quarters as the business
completes the transition to the post-
pandemic environment.
GEL MILLION
+74.1%
-21.2%
KEY OPERATING HIGHLIGHTS
Clinics
2Q21
VS.
▪ 2Q22
Change y-o-y
1H21
VS.
■ 1H22
Number of admissions ('000)
Number of registered patients ('000)
Diagnostics
565.1
568.3
497.5
600.8
-12.0%
+5.7%
1,022.3
568.3
1,136.1
600.8 +5.7%
Change y-o-y
+11.1%
Number of patients served ('000)
Number of total tests performed ('000)
Number of non-COVID tests performed ('000)
281
641
542
211 -24.9%
506
539 -15.9%
1,175
509
-6.2%
1,025
555 +9.7%
1,298
+10.5%
Georgia Capital PLC | General note: All figures are presented excluding Medical Centre University Clinic (HTMC). 1. Excluding IFRS 16. 2. Total revenue excludes eliminations between the clinics & diagnostics business lines.
1,111 +8.4%
74
14View entire presentation